Purpose.—To update key recommendations of the American Society of Clinical
Oncology/College of American Pathologists estrogen receptor (ER) and progesterone …

PURPOSE To update key recommendations of the American Society of Clinical
Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) …

Purpose To develop a guideline to improve the accuracy of immunohistochemical (IHC)
estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the …

Purpose: To develop a guideline to improve the accuracy of immunohis tochemical (IHC)
estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the …

Context.—Estrogen receptor and progesterone receptor status is assessed on all newly
diagnosed, invasive breast carcinomas and in recurrences to determine patient eligibility for …

Estrogen receptor (ER) status in breast cancer is currently the most important predictive
biomarker that determines breast cancer prognosis after treatment with endocrine therapy …

Estrogen receptor (ER) status is a strong predictor of response to hormonal therapy in breast
cancer patients. Presence of ER and level of expression have been shown to correlate with …

Background Guidelines for the use of chemotherapy and endocrine therapy recently
recommended that estrogen receptor (ER) status be considered positive if≥ 1% of tumor …

The NCCN Task Force on Estrogen Receptor and Progesterone Receptor Testing in Breast
Cancer by Immunohistochemistry was convened to critically evaluate the extent to which the …

The estrogen receptor (ER) is a regulator of cellular growth, proliferation, and differentiation.
In addition to having prognostic value, ER is the most important biologic marker of …